Patents by Inventor Andrew Graham Bowie

Andrew Graham Bowie has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Vaccinia virus protein A46 peptide and use thereof
    Patent number: 8722052
    Abstract: A peptide for inhibiting Toll-like receptor 4 (TLR4) signalling comprising the amino acid sequence of SEQ ID NO. 4, SEQ ID NO 55, SEQ ID NO 68, SEQ ID NO. 69, SEQ ID NO 70, SEQ ID NO 71, SEQ ID NO 72, SEQ ID NO 79, SEQ ID NO 82, SEQ ID NO 85, SEQ ID NO 88, SEQ ID NO 91, SEQ ID NO 94, SEQ ID NO 97, SEQ ID NO 100, SEQ ID NO 103, SEQ ID NO 106, SEQ ID NO 109, SEQ ID NO 112, or SEQ ID NO 115. The peptide may comprise a delivery sequence such as a cationic peptide.
    Type: Grant
    Filed: November 17, 2009
    Date of Patent: May 13, 2014
    Assignee: The Provost, Fellows, Foundation Scholars, and the other members of Board, of the College of the Holy and Undivided Trinity of Queen Elizabeth, near Dublin
    Inventors: Andrew Graham Bowie, Barry Noel Harrington, Tatyana Sergeevna Lysakova, Brian Keogh
  • A VACCINIA VIRUS PROTEIN A46 PEPTIDE AND USE THEREOF
    Publication number: 20110293641
    Abstract: A peptide for inhibiting Toll-like receptor 4 (TLR4) signalling comprising the amino acid sequence of SEQ ID NO. 4, SEQ ID NO 55, SEQ ID NO 68, SEQ ID NO. 69, SEQ ID NO 70, SEQ ID NO 71, SEQ ID NO 72, SEQ ID NO 79, SEQ ID NO 82, SEQ ID NO 85, SEQ ID NO 88, SEQ ID NO 91, SEQ ID NO 94, SEQ ID NO 97, SEQ ID NO 100, SEQ ID NO 103, SEQ ID NO 106, SEQ ID NO 109, SEQ ID NO 112, or SEQ ID NO 115. The peptide may comprise a delivery sequence such as a cationic peptide.
    Type: Application
    Filed: November 17, 2009
    Publication date: December 1, 2011
    Inventors: Andrew Graham Bowie, Barry Noel Harrington, Tatyana Sergeevna Lysakova, Brian Keogh
  • Orthopoxvirus vectors, genes and products thereof
    Publication number: 20090143289
    Abstract: An orthopoxvirus vector, such as vaccinia, is described in which the A46R protein from vaccinia, or a closely related protein from any orthopoxvirus is not expressed or is expressed but is non-functional. Also described is the use of a vaccinia virus A46R protein or a closely related protein from any orthopoxvirus, or a functional peptide, peptidometic, fragment or derivative thereof, or a DNA vector expressing any of the above in the modulation and/or inhibition of IL1R/TLR superfamily signalling.
    Type: Application
    Filed: April 30, 2008
    Publication date: June 4, 2009
    Inventors: Luke Anthony John O'Neill, Andrew Graham Bowie, Julianne Stack, Geoffrey Lilley Smith, Ismar Rocha Haga